Adelaide, Australia, 27 January 2022: Australian medical technology company LBT Innovations Limited (ASX: LBT) (LBT or the Company), a leader in medical technology automation using artificial intelligence, is pleased to release its Appendix 4C – Quarterly Cashflow report and business update for the quarter ended 31 December 2021 (the Quarter). All financial results are in Australian dollars and are unaudited.
Key Highlights
-
Transformational acquisition of Clever Culture Systems Joint Venture
-
FDA Clearance for MRSA analysis module – available for customers in the United States
-
10 Advanced sales opportunities, back-to-back product evaluations completed in Europe
-
31 December 2021 cash balance of $6.3 million after settlement of the CCS acquisition
For more information, download the attached PDF.
Download this document
